Yongping Crawford

• Experienced team lead with in-depth understanding of drug development processes; minimum 5 years of experience (5-10 years) in each of the following areas: Research, Biologic Development (antibody development and protein science), Early Development (CMC and other IND enabling activities).
• R&D project team lead for autoimmune/inflammatory diseases and CMC/Development project team lead for immuno-oncology and high concentration ocular projects
• Responsible for evaluating new target proposals and candidate nominations at Proteologix and NGMbio
• Senior management team member at Proteologix responsible for strategic planning
• Strong knowledge and expertise in multi-specific molecules targeting autoimmune, inflammatory diseases, and IO (including NK and T cell engager platforms)
• Recipient of Roche Pharma “NEXT” award in the “Pipeline” category from Roche Headquarter, Basel
• Strong communication and organization skills, effectively participated in multifunctional teams and IND fillings
• Funder of Proteologix, a Lily Asia and Orbimed ventures funded startup
• Key member in series A and A+ fundraising and responsible for presenting company projects and investor Q/A
• Well connected with MBC Biolab (biotech startup) networks

• Roche Pharma “NEXT” Award in the Pipeline category, 2016, Roche Headquarter, Basel
• Genentech Technical Transformation Innovation Award, 2015
• Key Contributor Award, 2015
• AACR-Busch Scholar-in-Training Award, 2004
• Regents Fellowship, University of California, San Francisco, 2001-2004

• Session chair for BioProcess International conference, 2020
• Session chair for BioProcess International West, 2019
• Session chair for Next Generation Protein Therapeutics & Bioconjugates Summit, 2019
• Symposium chair at AACR annual meeting as a postdoctoral fellow, 2009

• Shatz W, Hass PE, Mathieu M, Kim HS, Leach K, Zhou M, Crawford Y, Shen A, Wang K, Chang DP, Maia M, Crowell SR, Dickmann L, Scheer JM, Kelley RF.
  Contributions of antibody hydrodynamic size to vitreal clearance revealed through rabbit studies using a species-matched Fab.
  Mol. Pharm, 2016, Sept 6;13(9):2996-3003
• Yip S, Joly J, Snedecor B, Shen A, Crawford Y.
  Complete knockout of the lactate dehydrogenase A gene is lethal in pyruvate dehydrogenase kinase 1, 2, 3 downregulated CHO cells
  Mol. Biotechnology. 2014 Sept;56(9):833-8
• Crawford Y*, Zhou M, Hu Z, Joly J, Snedecor B, Shen A, Gao A.
  * Corresponding author
  Fast identification of reliable hosts for target cell line development from a limited genome screening using combined φC31 integrase and CRE-Lox technologies.
  Biotechnology Prog. 2013 Sept-Oct;29(5):1307-15
• Zhou M, Crawford Y, Ng D, Tung J, Pynn AF, Meier A, Yuk IH
  Decreasing lactate level and increasing antibody production in Chinese Hamster Ovary cells by reducing the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
  J Biotechnol. 2011 April;153(1-2):27-34
• Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, Tan C, Kolumam G, Vernes JM, Eastham-Anderson J, Haughney P, Kowanetz M, Hagenbeek T, Kasman I, Reslan HB, Ross J, Van Bruggen N, Carano RA, Meng YJ, Hongo JA, Stephan JP, Shibuya M, Ferrara N.
  PIGF blockage does not inhibit angiogenesis during primary tumor growth.
  Cell, 2010 Apr; 141(1):166
• Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N.
  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumor refractory to anti-VEGF treatment.
  Cancer Cell, 2009 Jan;15(1):21-34
• Crawford Y, and Ferrara N.
  Tumor and stroma pathways mediating refractoriness/resistance to anti-angiogenic therapies.
  Trends Pharmacol Sci. 2009 Dec;30(12):624-30
• Crawford Y, and Ferrara N.
  VEGF inhition: insights from preclinical and clinical studies
  Cell Tissue Res. 2009 Jan; 335(1):262-9
• Dumont N, Crawford Y, Sigaroudinia M, Nagrani SS, Wilson MB, Buehring GC, Turashvili G, Aparicio S, Gauthier ML, Fordyce, C, McDermott K, Tlsty TD.
  Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy
  Breast Cancer Res. 2009 11(6):R87
• Crawford Y, and Ferrara N
  Mouse models to investigate anti-cancer effects of VEGF inhibitors.
  Method in Enzymology 2008;445:125-139.
• Dumont N, Wilson, M, Crawford Y, Reynolds P, Sigaroudinia M, and Tlsty T.
  Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.
  PNAS, 2008 Sep; 105(39):14867-72
• Red-horse K, Crawford Y, Shojaei F, Ferrara N.
  Endothelium-microenvironment interactions in the developing embryo and in the adult.
  Developmental Cell. 2007 Feb; 12(2):181-94.
• Berman H, Zhang J, Crawford Y, Gauthier M, Fordyce C, McDermott K, Sigaroudinia M, Kozakiewicz K, Tlsty T
  Genentic and epigenetic changes in mammary epithelial cells identify a subpopulation of cells involved in early carcinogenesis.
  Cold Spring Harb Symp Quant Biol. 2005;70:317-27
• Crawford Y, Gauthier M, Joubel A, Mantei K, Kozakiewicz K, Afshari C, Tlsty T
  Histologically normal human mammary epithelial cells with p16INK4a promoter hypermethylation over-express COX-2, promoting pre-malignant phenotypes
  Cancer Cell, 2004 March;5(3):236-273
• Tlsty T, Crawford Y, Holst C, Fordyce C, Zhang J, McDermott K, Kozakiewicz K, Gauthier M.
  Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis
  J Mammary Gland Biol Neoplasia. 2004 Jul;9(3)263-74
• Tlsty T, Romanov S, Kozakiewicz K, Holst C, Haupt L, Crawford Y
  Loss of chromosomal integrity in human mammary epithelial cells subsequent to escape from senescence.
  J Mammary Gland Biol Neoplasia. 2001 Apr;6(2):235

Targeted integration of nucleic acids WO2019126634A2